KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Net Income: 2012-2025

Historic Net Income for Sarepta Therapeutics (SRPT) over the last 12 years, with Jun 2025 value amounting to -$447.6 million.

  • Sarepta Therapeutics' Net Income fell 7028.08% to -$447.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$248.7 million, marking a year-over-year decrease of 627.64%. This contributed to the annual value of $235.0 million for FY2024, which is 143.83% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Net Income stood at -$447.6 million for Q2 2025, which was down 381.84% from $158.8 million recorded in Q4 2024.
  • In the past 5 years, Sarepta Therapeutics' Net Income ranged from a high of $158.8 million in Q4 2024 and a low of -$516.8 million during Q1 2023.
  • Moreover, its 3-year median value for Net Income was $6.5 million (2024), whereas its average is -$83.2 million.
  • As far as peak fluctuations go, Sarepta Therapeutics' Net Income skyrocketed by 248.80% in 2024, and later slumped by 7,028.08% in 2025.
  • Over the past 5 years, Sarepta Therapeutics' Net Income (Quarterly) stood at -$122.0 million in 2021, then increased by 9.94% to -$109.9 million in 2022, then soared by 141.44% to $45.5 million in 2023, then soared by 248.80% to $158.8 million in 2024, then crashed by 7,028.08% to -$447.6 million in 2025.
  • Its Net Income was -$447.6 million in Q2 2025, compared to $158.8 million in Q4 2024 and $33.6 million in Q3 2024.